Open-Label Extension and Safety Study of Talazoparib

NCT02921919 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Talazoparib

Sponsor

Pfizer

Collaborators

[object Object]